(Sharecast News) - GSK said on Friday that it has sold its remaining 4.2% stake in consumer health business Haleon, which it spun off in July 2022.
The pharmaceutical company sold just over 385m ordinary shares in Haleon at 324p each, raising gross proceeds of about £1.25bn.
GSK initially retained a 12.9% stake in Haleon, but had since sold stakes in May 2023, October 2023 and January 2024.
"GSK's exit of its position in Haleon is consistent with its previous commitments to monetise its holding in a disciplined manner," it said.
Glaxosmithkline (GSK)
Haleon (HLN)
